Analyst Ratings For Blueprint Medicines
Portfolio Pulse from Benzinga Insights
Analysts have provided a range of ratings for Blueprint Medicines (NASDAQ:BPMC) over the past three months, with a majority being bullish. The average 12-month price target has increased by 4.13% to $120.17. Blueprint Medicines has shown significant revenue growth but faces challenges in debt management and return on equity.
October 24, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have shown a bullish sentiment towards Blueprint Medicines, with an increase in the average price target to $120.17. The company has demonstrated strong revenue growth but faces challenges in debt management and return on equity.
The majority of analysts have given bullish ratings, and the average price target has increased, indicating positive sentiment. The company's strong revenue growth supports this outlook. However, challenges in debt management and return on equity could pose risks, but the overall sentiment remains positive.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100